

# Investor Statement

## Access to Medicine Index

The goal of investors is to create long-term shareholder value in the companies in which they invest. This potential is maximized by investing in well-managed, high quality companies, where the management team have considered fully the range of business risks and opportunities facing their companies, and taken appropriate action to manage these. Alongside assessment of traditional financial risks and opportunities, there is growing recognition among the investment community of the potential for environmental, social and governance (ESG) factors to impact the financial performance of companies. As such, investors are also seeking for companies to demonstrate effective management of ESG factors.

We believe the issue of access to medicine in developing countries can present potentially significant business impacts for global companies in the pharmaceutical sector. As greater emphasis is placed on accessing new markets as a source for future industry growth, pharmaceutical companies are brought into ever closer contact with access to medicine issues in developing countries. Mismanagement of these issues can impact negatively on political relationships and corporate brands and encumber market access. On the other hand, if pharmaceutical companies act responsibly and with foresight, commercial potential can be unlocked.

As investors, we seek assurances that the management of the companies in which we invest have fully considered the risks and opportunities of this issue, and have effective policies and processes for dealing with the challenges. By taking management of this issue into account, alongside other key ESG and financial issues, the investment community can better assess the long-term investment value of such companies. We are increasingly reviewing corporate approaches to access to medicine and associated aspects of intellectual property as a key strategic consideration in our analysis of the sector, where this is appropriate to do so.

It is in this context that the investors listed below welcome the development of analytical tools such as the Access to Medicine Index, which may be used by investors to assess companies' management of the issue, based on information obtained from their reporting activities.

By our explicit inclusion in this statement, we are agreed on the following:

- We believe the issue of access to medicine is potentially material to long-term shareholder value creation, and is a potentially relevant consideration when forming views on the strategic positioning of companies in the pharmaceutical sector. We welcome the Access to Medicine Foundation's efforts to develop a credible, transparent and independent tool, which could be useful with regards to specific issue;
- We consider that pharmaceutical companies have an important role to play in addressing the access to medicine issue;
- We will review and take into account the analysis generated from the Index as appropriate in the ESG analysis we conduct on the companies we invest in;
- We hope that the Index will contribute towards creating greater awareness within the industry of this important issue, and act as a tool for highlighting leadership and good practice, as well as gaps and challenges;
- We will provide investor input into the evolution of the Index to ensure it considers the investment perspective as appropriate and remains dynamic and relevant to the debate.

We would encourage other investors to join us in this statement.

INVESTORS


CONTACTS

Investor

Signatory Contact

Achmea	Jeroen Wiercx
ACTIAM	Colette Grosscutt
Adrian Dominican Sisters	Donna Meyer
AMP Capital	Ian Woods
Amundi Asset Management	Lai Ly
APG	Els Knoope
ASN Bank	Piet Sprengers
ASR Nederland NV	Jack Julicher
Australian Ethical Investment	Stuart Palmer
Aviva Investors	Steve Waygood
Bank J. Safra Sarasin	Guillaume Krepper
BMO Global Asset Management	Yo Takatsuki
BNP Paribas Investment Partners	Helena Viñes Fiestas
Boston Common Asset Management	Lauren Compere
Calvert Investments	Stuart Dalheim
Candriam Investors Group	Sophie Deleuze
Central Finance Board of the Methodist Church	Christophe Borysiewicz
Church of Sweden	Sara Nordbrand
ClearBridge Investments	Marshall Gordon
CM-CIC Asset Management	Martine Leonard
Dana Investment Advisors	Ann Roberts
Daughters of Charity, Province of St. Louise	Donna Meyer
Dignity Health	Donna Meyer
Domini Impact Investments LLC	Carole Laible
Ecofi Investissements	François Lett
EdenTree Investment Management	Ketan Patel
Epworth Investment Management	Christophe Borysiewicz
Ethos	Yola Biedermann
Hermes Investment Management	Natacha Dimitrijevic
Impax Asset Management	Evie Paterson
ICCR	David Schilling
Janus Henderson	Antony Marsden
Kempen Capital Management	Valeria Dinershteyn
Local Government Super	Bill Hartnett
Mercy Health	Donna Meyer
Mercy Investment Services	Donna Meyer
Miller/Howard Investments	Luan Steinhilber
Mirova	Marina Iodice
MN	Nando van Kleef
Natixis Asset Management	Marina Iodice
NEI Investments	Robert Walker
NN Investment Partners	Adrie Heinsbroek
Nordea Asset Management	Magdalena Kettis
Northwest Coalition for Responsible Investment	Judy Byron
OFI Asset Management	Eric Van La Beck
Ohman	Fredric Nyström
Pax World Funds	Joe Keefe
PGGM	Rogier Snijdewind
Rathbone Greenbank Investments	Matt Crossman
Reynolds McVeigh Capital Management	Maria Egan
Robeco	Stijn Vanacker
Royal London Asset Management	Ashley Claxton
Schroders	Seema Suchak
SPH	Johan Reesink
SPMS	Jeroen Steenvoorden
Standard Life Investments	Andrew Mason
Stewart Investors	Amanda McCluskey
Stichting Algemeen Pensioenfonds Unilever Nederland	Michael Kaal
Sumitomo Mitsui Trust Asset Management	Seiji Kawazoe
The Congregation of St. Joseph	Donna Meyer
The Dai-ichi Life Insurance Company, Limited	Yasuhiro Miyata
The Sisters of St. Francis of Philadelphia	Nora Nash
Trillium Asset Management	Jonas Kron
Trinity Health	Cathy Rowan
Triodos Investment Management	Erik Breen
Trusteam Finance	Claire Berthier
USS	Daniel Summerfield
Vancity Investment Management	Kelly Hirsch
Varna Mutual Pension Insurance Company	Kaisa Ojainmaa
Vontobel	Natalie Ernst
Walden Asset Management	Heidi Soumerai
Zevin Asset Management	Pat Miguel Tomaino
Zürcher Kantonalbank	Eve Morelli

TOTAL ASSETS UNDER MANAGEMENT

IN EXCESS OF USD 10 TRILLION

For more information please contact Bowen Gu  
 bgu@accesstomedicinefoundation.org  
 + 31 (0) 20 21 53 535